These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 38295772

  • 1. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria.
    Pustotina O, Myers SH, Unfer V, Rasulova I.
    Gynecol Obstet Invest; 2024; 89(2):131-139. PubMed ID: 38295772
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
    Li X, Lin JF.
    Zhonghua Yi Xue Za Zhi; 2005 Dec 07; 85(46):3266-71. PubMed ID: 16409817
    [Abstract] [Full Text] [Related]

  • 5. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
    Zhao H, Xing C, Zhang J, He B.
    Reprod Health; 2021 Aug 18; 18(1):171. PubMed ID: 34407851
    [Abstract] [Full Text] [Related]

  • 6. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
    Pizzo A, Laganà AS, Barbaro L.
    Gynecol Endocrinol; 2014 Mar 18; 30(3):205-8. PubMed ID: 24351072
    [Abstract] [Full Text] [Related]

  • 7. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.
    Nordio M, Basciani S, Camajani E.
    Eur Rev Med Pharmacol Sci; 2019 Jun 18; 23(12):5512-5521. PubMed ID: 31298405
    [Abstract] [Full Text] [Related]

  • 8. Serum uric acid/creatinine ratio and free androgen index are synergistically associated with increased risk of polycystic ovary syndrome in obese women.
    El-Eshmawy MM, Ibrahim A, Bahriz R, Shams-Eldin N, Mahsoub N.
    BMC Endocr Disord; 2022 Dec 13; 22(1):315. PubMed ID: 36514085
    [Abstract] [Full Text] [Related]

  • 9. Potential role and therapeutic interests of myo-inositol in metabolic diseases.
    Croze ML, Soulage CO.
    Biochimie; 2013 Oct 13; 95(10):1811-27. PubMed ID: 23764390
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome.
    Fruzzetti F, Capozzi A, Canu A, Lello S.
    Gynecol Endocrinol; 2019 Jun 13; 35(6):506-510. PubMed ID: 30612488
    [Abstract] [Full Text] [Related]

  • 12. A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women.
    Benelli E, Del Ghianda S, Di Cosmo C, Tonacchera M.
    Int J Endocrinol; 2016 Jun 13; 2016():3204083. PubMed ID: 27493664
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
    Nordio M, Proietti E.
    Eur Rev Med Pharmacol Sci; 2012 May 13; 16(5):575-81. PubMed ID: 22774396
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol.
    Laganà AS, Barbaro L, Pizzo A.
    Arch Gynecol Obstet; 2015 May 13; 291(5):1181-6. PubMed ID: 25416201
    [Abstract] [Full Text] [Related]

  • 16. Decreased Insulin Resistance by Myo-Inositol Is Associated with Suppressed Interleukin 6/Phospho-STAT3 Signaling in a Rat Polycystic Ovary Syndrome Model.
    Zhang Y, Li C, Zhang W, Zheng X, Chen X.
    J Med Food; 2020 Apr 13; 23(4):375-387. PubMed ID: 32045334
    [Abstract] [Full Text] [Related]

  • 17. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
    Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, Campedelli A, Simoncini T, Artini PG.
    Gynecol Endocrinol; 2012 Dec 13; 28(12):969-73. PubMed ID: 22612517
    [Abstract] [Full Text] [Related]

  • 18. Potential role of d-chiro-inositol in reducing oxidative stress in the blood of nonobese women with polycystic ovary syndrome.
    Simic D, Nikolic Turnic T, Dimitrijevic A, Zivadinovic A, Milosevic-Stevanovic J, Djuric D, Zivkovic V, Jakovljevic V.
    Can J Physiol Pharmacol; 2022 Jul 01; 100(7):629-636. PubMed ID: 35413205
    [Abstract] [Full Text] [Related]

  • 19. A Comparison of the Hormonal Profile of Early Androgenetic Alopecia in Men With the Phenotypic Equivalent of Polycystic Ovarian Syndrome in Women.
    Sanke S, Chander R, Jain A, Garg T, Yadav P.
    JAMA Dermatol; 2016 Sep 01; 152(9):986-91. PubMed ID: 27304785
    [Abstract] [Full Text] [Related]

  • 20. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients.
    Genazzani AD, Santagni S, Rattighieri E, Chierchia E, Despini G, Marini G, Prati A, Simoncini T.
    Gynecol Endocrinol; 2014 Jun 01; 30(6):438-43. PubMed ID: 24601829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.